Drug Trial Radar · NCT07062965
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 5, 2025
Primary completion
Jul 22, 2027
Study completion Nov 4, 2030
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.
Conditions
- Breast Cancer
Interventions
PF-07248144Drug
KAT6 inhibitor
FulvestrantDrug
Endocrine therapy
EverolimusDrug
mTOR inhibitor
ExemestaneDrug
Endocrine therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: From the date of randomization until disease progression or death due to any cause (up to approximately 2 years)
Locations
433 sites in 31 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology, LLC
Anchorage, Alaska · Recruiting
Ironwood Cancer & Research Centers
Chandler, Arizona · Recruiting
Banner Gateway Medical Center
Gilbert, Arizona · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Ironwood Cancer & Research Centers
Gilbert, Arizona · Recruiting
Ironwood Cancer & Research Centers
Glendale, Arizona · Recruiting
Ironwood Cancer & Research Centers
Goodyear, Arizona · Recruiting
Ironwood Cancer & Research Centers
Mesa, Arizona · Recruiting
Ironwood Cancer & Research Centers
Mesa, Arizona · Recruiting
Ironwood Cancer & Research Centers
Phoenix, Arizona · Recruiting
Ironwood Cancer & Research Centers
Scottsdale, Arizona · Recruiting
Highlands Oncology Group, PA
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group, PA
Rogers, Arkansas · Recruiting
Highlands Oncology Group, PA
Springdale, Arkansas · Recruiting
Oncura Health - Anaheim
Anaheim, California · Recruiting
Ventura County Hematology Oncology Specialists
Camarillo, California · Recruiting
Oncura Health - Fountain Valley
Fountain Valley, California · Recruiting
Oncura Health - Corporate (Central IDS & Regulatory Only)
Glendale, California · Recruiting
Oncura Health - Good Samaritan
Los Angeles, California · Recruiting
Dr. Karandeep Singh MD
Oxnard, California · Recruiting
Rolling Oaks Radiology - Oxnard
Oxnard, California · Recruiting
Ventura County Hematology Oncology Specialists
Oxnard, California · Recruiting
Rolling Oaks Radiology North Solar
Oxnard, California · Recruiting
Clinical and Translational Research Unit (CTRU)
Palo Alto, California · Recruiting
Stanford Cancer Center
Palo Alto, California · Recruiting
Stanford Women's Cancer Center
Palo Alto, California · Recruiting
Sansum Clinic
Santa Barbara, California · Recruiting
Sansum Clinic
Solvang, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California · Recruiting
Torrance Memorial Physician Network - Cancer Care
Torrance, California · Recruiting
Torrance Memorial Physician Network-Cancer Care
Torrance, California · Recruiting
Harbor-UCLA Medical Center
Torrance, California · Recruiting
Oncura Health - Valley Presbyterian
Van Nuys, California · Recruiting
Ventura County Hematology Oncology Specialists
Ventura, California · Recruiting
Rocky Mountain Cancer Centers LLP
Aurora, Colorado · Recruiting
Rocky Mountain Cancer Centers LLP
Boulder, Colorado · Recruiting
Rocky Mountain Cancer Centers LLP
Centennial, Colorado · Recruiting
Rocky Mountain Cancer Centers LLP
Colorado Springs, Colorado · Recruiting
Rocky Mountain Cancer Centers LLP
Colorado Springs, Colorado · Recruiting
Rocky Mountain Cancer Centers LLP
Denver, Colorado · Recruiting
Showing 40 of 433 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.